Verve Therapeutics, Inc. (VERV)

-2.28% (1D)

Market Cap	993.15M
Revenue (ttm)	59.61M
Net Income (ttm)	-181.01M
Shares Out	89.31M
EPS (ttm)	-2.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,065,216
Open	11.18
Previous Close	11.38
Day's Range	11.10 - 11.26
52-Week Range	2.87 - 11.41
Beta	1.67
Analysts	Buy
Price Target	14.75 (+32.64%)
Earnings Date	Aug 7, 2025

About VERV

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 274
• Stock Exchange: NASDAQ
• Ticker Symbol: VERV
• Website: https://www.vervetx.com

Financial Performance

In 2024, Verve Therapeutics's revenue was $32.33 million, an increase of 174.98% compared to the previous year's $11.76 million. Losses were -$198.71 million, -0.68% less than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for VERV stock is "Buy." The 12-month stock price forecast is $14.75, which is an increase of 32.64% from the latest price.

Price Target

$14.75

(32.64% upside)

Analyst Consensus: Buy